Navigation Links
New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders

Data to be Presented April 15th at EASL Conference in Barcelona, Spain

VANCOUVER and SAN DIEGO, CA, April 11, 2007 /PRNewswire-FirstCall/ - MIGENIX Inc. , a clinical-stage developer of drugs for infectious diseases, has received new top-line results confirming the previously announced clinical results (November 6, 2006) indicating evidence of clinical benefit, safety and tolerability in a Phase II study using the oral alpha-glucosidase inhibitor, celgosivir (MX-3253), in combination with pegylated interferon and ribavirin.

In addition to confirming the overall conclusions of the original study analysis, retesting resulted in a larger percentage of patients achieving an Early Virologic Response(x) ("EVR") rate with celgosivir plus peginterferon alfa-2b and ribavirin (the "triple combination") as compared to treatment with peginterferon alfa-2b and ribavirin alone (the "control treatment") in patients with chronic hepatitis C virus genotype 1 infections who were characterized as non-responders to prior therapy with optimized pegylated interferon plus ribavirin, achieving:

    -   42% (5/12) EVR with the celgosivir triple combination arm compared to

        10% (1/10) EVR in the control treatment arm. This compares with 33%

        (4/12) EVR (triple combination) vs 10% (1/10) (control treatment) in

        the original study results. (x) EVR = 2 log(10) or greater

        HCV viral load reduction at 12 weeks.


    -   1.63 log(10) (triple combination) mean HCV viral load reduction

        ("VLR") compared to a 0.92 log(10) VLR (control treatment). This

        compares with a 1.2 log(10) VLR (triple combination) vs a 0.4 log(10)

        VLR (control treatment) in the original study results.


    -   a more rapid onset of treatment effect as measured by VLR within the

        first 2 weeks of therapy in the triple combination as compared to the

        control treatment.

Thes
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
Post Your Comments:
(Date:4/24/2015)... 24, 2015 Hospira, Inc. (NYSE: ... of biosimilar therapies, spoke about the importance of extrapolation ... Generics Association (EGA) annual European Biosimilars Group conference in ... also announced the publication of a pivotal white paper ... full promise of biosimilars." Speaking at ...
(Date:4/24/2015)... Mass. , April 24, 2015  Blueprint ... BLU-554, a selective and potent inhibitor of fibroblast ... activity in models of hepatocellular carcinoma (HCC) that ... therapeutic candidate, BLU-554 induced complete tumor regression in ... an FGFR4-activating ligand at the highest dose levels. ...
(Date:4/23/2015)... IRVINE, Calif., April 23, 2015  Edwards Lifesciences Corporation (NYSE: ... of heart valves and hemodynamic monitoring, today reported net ... million, or $1.12 per diluted share.  Net income for ... or $0.56 per diluted share, and non-GAAP net income ... Net sales for the quarter ended March 31, 2015 ...
Breaking Medicine Technology:Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 2Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 3Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 4Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 5Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 6Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 7Blueprint Medicines Presents New Preclinical Data Demonstrating Its Drug Candidate BLU-554 Induces Significant Tumor Regression in Models of Hepatocellular Carcinoma 2Blueprint Medicines Presents New Preclinical Data Demonstrating Its Drug Candidate BLU-554 Induces Significant Tumor Regression in Models of Hepatocellular Carcinoma 3Edwards Lifesciences Reports First Quarter Results 2Edwards Lifesciences Reports First Quarter Results 3Edwards Lifesciences Reports First Quarter Results 4Edwards Lifesciences Reports First Quarter Results 5Edwards Lifesciences Reports First Quarter Results 6Edwards Lifesciences Reports First Quarter Results 7Edwards Lifesciences Reports First Quarter Results 8Edwards Lifesciences Reports First Quarter Results 9Edwards Lifesciences Reports First Quarter Results 10Edwards Lifesciences Reports First Quarter Results 11Edwards Lifesciences Reports First Quarter Results 12Edwards Lifesciences Reports First Quarter Results 13Edwards Lifesciences Reports First Quarter Results 14Edwards Lifesciences Reports First Quarter Results 15Edwards Lifesciences Reports First Quarter Results 16
...  Reportlinker.com announces that a new market ... catalogue: Triple Analysis: ... http://www.reportlinker.com/p0284888/Triple-Analysis-Apoptosis-Cancer-Vaccines-and-Antibodies.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This ... development strategies by the two mechanism/target/effect ...
... Research Institute (IDRI) announces today that GlaxoSmithKline (GSK) Biologicals ... equipment that will assist IDRI as it designs and ... the developing world. IDRI will apply the gift as ... tuberculosis, leishmaniasis, malaria, leprosy, and pandemic influenza. ...
Cached Medicine Technology:Triple Analysis: Apoptosis, Cancer Vaccines and Antibodies 2Triple Analysis: Apoptosis, Cancer Vaccines and Antibodies 3Triple Analysis: Apoptosis, Cancer Vaccines and Antibodies 4Triple Analysis: Apoptosis, Cancer Vaccines and Antibodies 5GlaxoSmithKline Donates Scientific Equipment to Advance IDRI's Global Health Mission 2
(Date:4/24/2015)... As the nation recognizes the Month ... of these young men and women, the “Alaska – ... their Families” presents a special training session on Adverse ... a better understanding of the effect of childhood trauma ... – civilian and military – who provide services and ...
(Date:4/24/2015)... The Fastest Fat Loss Week Ever, released by ... the Xtreme Fat Loss Diet, has been causing a lot ... that claims to help one lose belly fat in only ... prompting an investigative review. , "Our Fastest Fat Loss ... researching and experimenting with these methods on their clients with ...
(Date:4/24/2015)... On February 21st, 2015, Per Wickstrom had the ... contributor Karen Salkin at Durkin Entertainment’s EcoLuxe Lounge, sponsored ... of which Wickstrom is the founder. Making appearances at ... EcoLuxe Lounge is a gathering of some of the ... and services. Among the many roles that she has ...
(Date:4/24/2015)... Carinsurancequotesinfo.com has released a new blog post has ... qualify for auto insurance as a single parent. ... online, without having to follow a special process. The ... reduce their auto insurance expenses. The tips are presented ... , Clients can now visit an insurance brokerage website ...
(Date:4/24/2015)... Olive Fertility Centre is proud to announce that ... been honoured for his pioneering work in the field ... , “We are very pleased to have this ... at the forefront of fertility research and treatment for ... of Fertile Futures--a Canadian non-profit organization that provides fertility ...
Breaking Medicine News(10 mins):Health News:Coalition Presents Resiliency Training to Raise Awareness during Month of the Military Child (#MOTMC2015) 2Health News:Fastest Fat Loss Week Ever Review Revealed on Healthy & Fit Zone 2Health News:Karen Salkin Talks with Per Wickstrom at the 2015 EcoLuxe Lounge and the "Salute to the Oscars" Celebration 2Health News:Auto Insurance Discounts for Single Parents - How to Qualify for Low Rates 2Health News:Olive Fertility Centre Co-founder, Dr Al Yuzpe, Recognized as a Pioneer in Fertility Preservation 2
... - Fat substitutes used in popular snack foods to help ... Purdue University research. "These substitutes are meant to mimic ... in fat while providing a lower number of calories, but ... Swithers, professor of psychological sciences. "We didn,t study this in ...
... , WEDNESDAY, June 22 (HealthDay News) -- Researchers searching ... a promising possibility: an impairment in the ability of ... each other. In the study, researchers did brain ... 30 typically developing kids and 13 children with significant ...
... bypass surgery is considered the gold standard for most patients ... serious types of heart disease and one that affects thousands. ... favorable long-term outcomes for lower-risk patients with this condition who ... A more minimally invasive procedure than surgery, angioplasty ...
... Children born to mothers who smoked during pregnancy have lower ... of heart attack and stroke later in life, a new ... children and found that those whose mothers smoked during pregnancy ... compared to a normal level of 1.5 mmol/L in children ...
... The University of New Hampshire has launched a ... Sciences (CAAS) to promote international research in agricultural development ... College of Life Sciences and Agriculture (COLSA) at UNH ... of the CAAS Institute for Agricultural Resources and Regional ...
... UNC Lineberger Comprehensive Cancer Center, offers hope for people with ... disease characterized by excessive production of red blood cells. ... of stroke, and in some cases the disease is a ... cases are associated with a mutation in the JAK2 gene, ...
Cached Medicine News:Health News:Study: Trying to lose weight? Lose the fat substitutes 2Health News:Poor Brain 'Sync' a Possible Sign of Autism 2Health News:Poor Brain 'Sync' a Possible Sign of Autism 3Health News:Angioplasty with stents may be safe in long-term for low-risk heart patients 2Health News:Angioplasty with stents may be safe in long-term for low-risk heart patients 3Health News:UNH launches joint Sustainable Agro-Ecosystems Lab with Chinese Academy 2
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
Escherichia coli - For the qualitative detection of Escherichia coli 0157 and 0157:H7 in food products Accessories BinaxNOW EH E.coli 0157 & 0157:H7 Control Swab Pack (510-000) ...
... differential detection of circulating ... an antigen that is common ... malaria:plasmodium falciparum (P.f), plasmodium vivax ... Plasmodium malariae (P.m) in whole ...
Medicine Products: